scholarly journals Mammary and Extramammary Paget’s Disease Presented Different Expression Pattern of Steroid Hormone Receptors

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Songxia Zhou ◽  
Weixiang Zhong ◽  
Ruiqin Mai ◽  
Guohong Zhang

Background and Objectives. Paget’s disease (PD) is a rare intraepithelial adenocarcinoma, which is composed of mammary (MPD) and extramammary Paget’s disease (EMPD). Currently, the published literature contains scant data on expression pattern of steroid hormone receptors in MPD and EMPD. Methods. Expression of estrogen receptor (ER) and androgen receptor (AR) was evaluated in 88 MPD and 72 EMPD by using immunohistochemical staining and H-score method. Results. Positive expression of AR was significantly higher in EMPD (61.11%, 44/72) than in MPD (32.95%, 29/88) (P<0.001), while ER expression was positive 19.44% (14/72) in EMPD and only 9.09% (8/88) in MPD (P=0.059). ER-AR expression pattern was significantly different between MPD (3.41%, 3/88) and EMPD (16.67%, 12/72) (P<0.001). No difference of AR (P=0.301) or ER (P=0.239) expression was identified between invasive (48.57%, 51/105 of AR, and 11.43%, 12/105 of ER) and noninvasive PD. In MPD, no difference of AR expression between MPD alone (7/18, 38.89%) and MPD with underling ductal carcinoma of breast (22/70, 31.43%) was identified (P=0.548). In EMPD, expression of AR was 63.33% (38/60) in penoscrotal EMPD. Conclusion. Our current results indicate that MPD and EMPD presented different expression pattern of AR and ER and would help to further identify the molecular subtype of MPD and EMPD for adjuvant hormonal therapy, especially for patients with penoscrotal EMPD.

1984 ◽  
Vol 46 (5) ◽  
pp. 1118-1122 ◽  
Author(s):  
Yoshihisa FUJII ◽  
Nobuyuki SHIRAISHI ◽  
Etsuji MATSUNAGA ◽  
Susumu TAKAYASU ◽  
Toshitaka NAKAMURA

2007 ◽  
Vol 69 (3) ◽  
pp. 273-276
Author(s):  
Satoko KUMAZAWA ◽  
Kou DAN ◽  
Teiichi MASUDA ◽  
Kazunori URABE ◽  
Masutaka FURUE

2021 ◽  
Vol 41 (1) ◽  
pp. 219-226
Author(s):  
AYA KAWAGUCHI ◽  
JUN AKIBA ◽  
REIICHIRO KONDO ◽  
EIJI SADASHIMA ◽  
SACHIKO OGASAWARA ◽  
...  

Author(s):  
J. S. Anjana ◽  
P. Rema ◽  
S. Suchetha ◽  
J. Siva Ranjith ◽  
Amrita B. Rao ◽  
...  

Diagnostics ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1086
Author(s):  
Shun Ohmori ◽  
Yu Sawada ◽  
Natsuko Saito-Sasaki ◽  
Sayaka Sato ◽  
Yoko Minokawa ◽  
...  

Extramammary Paget’s disease is recognized as an apocrine-origin cutaneous tumor and is localized in the intraepithelial skin lesion. However, its advanced form is intractable, and there is currently no therapeutic option with a satisfactory level of clinical outcome. Therefore, it is of great importance to identify a potential biomarker to estimate tumor advancement in extramammary Paget’s disease. Dermcidin is an antimicrobial peptide derived from the eccrine gland and is identified as a biomarker in various malignancies. To investigate the potential of dermcidin in extramammary Paget’s disease, we investigated dermcidin expression in tumors using the immunostaining technique. Although previous studies have reported that extramammary Paget’s disease has no positive staining against dermcidin, 14 out of 60 patients showed positive staining of dermcidin in our study. To clarify the characteristics of positive dermcidin in extramammary Paget’s disease, we investigated the clinical characteristics of positive dermcidin extramammary Paget’s disease patients. Positive dermcidin patients showed a significantly high frequency of lymph node metastasis. We next investigated the impact of positive dermcidin on overall survival. Univariate analysis identified that positive dermcidin showed a significantly increased hazard ratio in overall survival, suggesting that dermcidin might be a prognostic factor for extramammary Paget’s disease.


Sign in / Sign up

Export Citation Format

Share Document